Efanesoctocog alfa

ApprovedRecruiting

1 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

May 21, 2025 → Dec 1, 2028

NCT ID

NCT06940830

About Efanesoctocog alfa

Efanesoctocog alfa is a approved stage product being developed by Swedish Orphan Biovitrum for Hemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06940830. Target conditions include Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A were approved

Approved (20) Terminated (3) Active (0)

✅EmicizumabRocheApproved

✅BenefixPfizerApproved

✅Nonacog alfaPfizerApproved

✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved

✅Recombinant Factor IX CoagulationPfizerApproved

✅Moroctocog alfa(AF-CC)PfizerApproved

✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06940830	Approved	Recruiting	May 21, 2025	Dec 1, 2028	Hemophilia A
NCT06716814	Phase 3	Recruiting	Mar 6, 2025	Mar 1, 2027	Severe Haemophilia A
NCT06579144	Phase 1	Recruiting	Feb 24, 2025	May 28, 2026	Hemophilia A
NCT06752850	Approved	Active	Dec 19, 2024	Dec 1, 2026	Haemophilia A (Moderate or Severe)
NCT05817812	Phase 3	Active	Jul 31, 2023	Jun 12, 2026	Hemophilia A, Severe

Competing Products

20 competing products in Hemophilia A

See all competitors

Product	Company	Stage	Hype Score
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab + rFVIIa + aPCC	Chugai Pharmaceutical	Phase 3	40
Human Coagulation Factor VIII	Chugai Pharmaceutical	Phase 3	47
Emicizumab	Chugai Pharmaceutical	Phase 3	47
Emicizumab + Factor VIII (FVIII)	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Roche	Phase 3	40
HEMLIBRA	Johnson & Johnson	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Emicizumab	Roche	Approved	47
Emicizumab	Roche	Phase 3	44
SPK-8011QQ	Roche	Phase 1/2	39
NXT007	Roche	Phase 1/2	39
Emicizumab Injection	Roche	Phase 2	35
Bypassing Agents + FVIII Replacement	Roche	Pre-clinical	26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086	Pfizer	Phase 2	35
Nonacog Alfa (Genetical Recombination)	Pfizer	Pre-clinical	26
Refacto AF	Pfizer	Pre-clinical	18
PF-06838435/ fidanacogene elaparvovec	Pfizer	Phase 3	44
ReFacto AF	Pfizer	Phase 3	40